Trial Profile
A Phase I Study of RG3638 as a Single Agent in Patients with Solid Tumors, and RG3638 in Combination with Erlotinib in Patients with Met diagnostic-positive Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2018
Price :
$35
*
At a glance
- Drugs Onartuzumab (Primary) ; Erlotinib
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 06 Sep 2011 New trial record